Global Orphan Drugs Market 2023-2027

Description

List of Tables

Technavio has been monitoring the orphan drugs market and is forecast to grow by $170.8 bn during 2022-2027, accelerating at a CAGR of 14.02% during the forecast period. Our report on the orphan drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by robust pipeline and recent drug approvals, rising incidence of rare diseases, and availability of incentives for orphan drug development.

Technavio's orphan drugs market is segmented as below:

By Distribution Channel

Hospital pharmacy
Specialty pharmacy
Retail pharmacy
Others

By Product

Biologics
Non-biologics

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the strategic focus on alliances, partnerships, and M&A as one of the prime reasons driving the orphan drugs market growth during the next few years. Also, the emergence of combination therapies and novel targets and rising demand for genetic tests and protein biomarkers will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the orphan drugs market covers the following areas:

Orphan drugs market sizing
Orphan drugs market forecast
Orphan drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading orphan drugs market vendors that include AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, bluebird bio Inc., Bristol Myers Squibb Co., CSL Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Pfizer Inc., Ractigen Therapeutics, Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Vertex Pharmaceuticals Inc. Also, the orphan drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR46586

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global orphan drugs market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on Global orphan drugs market 2017 - 2021 ($ billion)
4.2 Distributed Channel Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Distributed Channel Segment 2017 - 2021 ($ billion)
4.3 Product Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Product Segment 2017 - 2021 ($ billion)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ billion)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Distribution Channel

6.1 Market segments
Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)
6.2 Comparison by Distribution Channel
Exhibit 32: Chart on Comparison by Distribution Channel
Exhibit 33: Data Table on Comparison by Distribution Channel
6.3 Hospital pharmacy - Market size and forecast 2022-2027
Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
6.4 Specialty pharmacy - Market size and forecast 2022-2027
Exhibit 38: Chart on Specialty pharmacy - Market size and forecast 2022-2027 ($ billion)
Exhibit 39: Data Table on Specialty pharmacy - Market size and forecast 2022-2027 ($ billion)
Exhibit 40: Chart on Specialty pharmacy - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Specialty pharmacy - Year-over-year growth 2022-2027 (%)
6.5 Retail pharmacy - Market size and forecast 2022-2027
Exhibit 42: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
Exhibit 43: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
Exhibit 44: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
6.6 Others - Market size and forecast 2022-2027
Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ billion)
Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
6.7 Market opportunity by Distribution Channel
Exhibit 50: Market opportunity by Distribution Channel ($ billion)
Exhibit 51: Data Table on Market opportunity by Distribution Channel ($ billion)

7 Market Segmentation by Product

7.1 Market segments
Exhibit 52: Chart on Product - Market share 2022-2027 (%)
Exhibit 53: Data Table on Product - Market share 2022-2027 (%)
7.2 Comparison by Product
Exhibit 54: Chart on Comparison by Product
Exhibit 55: Data Table on Comparison by Product
7.3 Biologics - Market size and forecast 2022-2027
Exhibit 56: Chart on Biologics - Market size and forecast 2022-2027 ($ billion)
Exhibit 57: Data Table on Biologics - Market size and forecast 2022-2027 ($ billion)
Exhibit 58: Chart on Biologics - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
7.4 Non-biologics - Market size and forecast 2022-2027
Exhibit 60: Chart on Non-biologics - Market size and forecast 2022-2027 ($ billion)
Exhibit 61: Data Table on Non-biologics - Market size and forecast 2022-2027 ($ billion)
Exhibit 62: Chart on Non-biologics - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Non-biologics - Year-over-year growth 2022-2027 (%)
7.5 Market opportunity by Product
Exhibit 64: Market opportunity by Product ($ billion)
Exhibit 65: Data Table on Market opportunity by Product ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ billion)
Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ billion)
Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ billion)
Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 UK - Market size and forecast 2022-2027
Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ billion)
Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.9 Canada - Market size and forecast 2022-2027
Exhibit 95: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
Exhibit 96: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
Exhibit 97: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.10 China - Market size and forecast 2022-2027
Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ billion)
Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ billion)
Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)
9.11 Germany - Market size and forecast 2022-2027
Exhibit 103: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
Exhibit 104: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
Exhibit 105: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ billion)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 115: AbbVie Inc. - Overview
Exhibit 116: AbbVie Inc. - Product / Service
Exhibit 117: AbbVie Inc. - Key news
Exhibit 118: AbbVie Inc. - Key offerings
12.4 Alnylam Pharmaceuticals Inc.
Exhibit 119: Alnylam Pharmaceuticals Inc. - Overview
Exhibit 120: Alnylam Pharmaceuticals Inc. - Product / Service
Exhibit 121: Alnylam Pharmaceuticals Inc. - Key news
Exhibit 122: Alnylam Pharmaceuticals Inc. - Key offerings
12.5 Astellas Pharma Inc.
Exhibit 123: Astellas Pharma Inc. - Overview
Exhibit 124: Astellas Pharma Inc. - Product / Service
Exhibit 125: Astellas Pharma Inc. - Key news
Exhibit 126: Astellas Pharma Inc. - Key offerings
12.6 AstraZeneca Plc
Exhibit 127: AstraZeneca Plc - Overview
Exhibit 128: AstraZeneca Plc - Product / Service
Exhibit 129: AstraZeneca Plc - Key news
Exhibit 130: AstraZeneca Plc - Key offerings
12.7 bluebird bio Inc.
Exhibit 131: bluebird bio Inc. - Overview
Exhibit 132: bluebird bio Inc. - Product / Service
Exhibit 133: bluebird bio Inc. - Key offerings
12.8 Bristol Myers Squibb Co.
Exhibit 134: Bristol Myers Squibb Co. - Overview
Exhibit 135: Bristol Myers Squibb Co. - Product / Service
Exhibit 136: Bristol Myers Squibb Co. - Key news
Exhibit 137: Bristol Myers Squibb Co. - Key offerings
12.9 CSL Ltd.
Exhibit 138: CSL Ltd. - Overview
Exhibit 139: CSL Ltd. - Business segments
Exhibit 140: CSL Ltd. - Key news
Exhibit 141: CSL Ltd. - Key offerings
Exhibit 142: CSL Ltd. - Segment focus
12.10 F. Hoffmann La Roche Ltd.
Exhibit 143: F. Hoffmann La Roche Ltd. - Overview
Exhibit 144: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 145: F. Hoffmann La Roche Ltd. - Key news
Exhibit 146: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 147: F. Hoffmann La Roche Ltd. - Segment focus
12.11 Gilead Sciences Inc.
Exhibit 148: Gilead Sciences Inc. - Overview
Exhibit 149: Gilead Sciences Inc. - Product / Service
Exhibit 150: Gilead Sciences Inc. - Key news
Exhibit 151: Gilead Sciences Inc. - Key offerings
12.12 GlaxoSmithKline Plc
Exhibit 152: GlaxoSmithKline Plc - Overview
Exhibit 153: GlaxoSmithKline Plc - Business segments
Exhibit 154: GlaxoSmithKline Plc - Key news
Exhibit 155: GlaxoSmithKline Plc - Key offerings
Exhibit 156: GlaxoSmithKline Plc - Segment focus
12.13 Ipsen Pharma
Exhibit 157: Ipsen Pharma - Overview
Exhibit 158: Ipsen Pharma - Business segments
Exhibit 159: Ipsen Pharma - Key offerings
Exhibit 160: Ipsen Pharma - Segment focus
12.14 Johnson and Johnson Services Inc.
Exhibit 161: Johnson and Johnson Services Inc. - Overview
Exhibit 162: Johnson and Johnson Services Inc. - Business segments
Exhibit 163: Johnson and Johnson Services Inc. - Key news
Exhibit 164: Johnson and Johnson Services Inc. - Key offerings
Exhibit 165: Johnson and Johnson Services Inc. - Segment focus
12.15 Merck and Co. Inc.
Exhibit 166: Merck and Co. Inc. - Overview
Exhibit 167: Merck and Co. Inc. - Business segments
Exhibit 168: Merck and Co. Inc. - Key news
Exhibit 169: Merck and Co. Inc. - Key offerings
Exhibit 170: Merck and Co. Inc. - Segment focus
12.16 Novartis AG
Exhibit 171: Novartis AG - Overview
Exhibit 172: Novartis AG - Business segments
Exhibit 173: Novartis AG - Key offerings
Exhibit 174: Novartis AG - Segment focus
12.17 Ractigen Therapeutics
Exhibit 175: Ractigen Therapeutics - Overview
Exhibit 176: Ractigen Therapeutics - Product / Service
Exhibit 177: Ractigen Therapeutics - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 178: Inclusions checklist
Exhibit 179: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 180: Currency conversion rates for US$
13.4 Research methodology
Exhibit 181: Research methodology
Exhibit 182: Validation techniques employed for market sizing
Exhibit 183: Information sources
13.5 List of abbreviations
Exhibit 184: List of abbreviations